Patents by Inventor Paul R. Kemp

Paul R. Kemp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to determine TGF-beta
    Patent number: 7094550
    Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C?O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: August 22, 2006
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, Paul R. Kemp
  • Method to determine TGF-beta
    Publication number: 20020182659
    Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (1): 1
    Type: Application
    Filed: March 26, 2002
    Publication date: December 5, 2002
    Applicant: NeoRx Corporation
    Inventors: David J. Grainger, Paul R. Kemp
  • Method to determine TGF-&bgr;
    Patent number: 6395494
    Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C═O or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1-C4)alkyl or H and R6 is I, O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 28, 2002
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, Paul R. Kemp